[Federal Register Volume 71, Number 6 (Tuesday, January 10, 2006)]
[Notices]
[Pages 1544-1545]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-86]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Polysaccharide Derived Nitric Oxide Releasing Carbon Bound 
Diazeniumdiolates

Joseph A. Hrabie et al. (NCI)
U.S. Provisional Application No. 60/731,946 filed 31 Oct 2005 (HHS 
Reference No. E-279-20050-US-01)
Licensing Contact: John Stansberry; 301/435-5236; [email protected]

    The invention discloses a method for producing nitric oxide(NO)-
releasing derivatives of any material containing a reducing sugar 
component. It may be used to produce NO-releasing cotton bandages or 
surgical fabrics, cellulose filters or dialysis membranes, and drug 
formulating/compounding agents to prevent stomach irritation. The 
method involves incorporation of a diazeniumdiolate (-
N2O2) group at one or more carbons via the base-
catalyzed replacement of acidic hydrogens and is thus compatible with 
traditional polysaccharide processing techniques. Monosaccharides such 
as glucose may also be derivatized.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

Hydropneumatic Fluid Control for a Cell Culturing System

Alexandr Chanturiya, Svetlana Glushakova, and Joshua Zimmerberg (NICHD)
U.S. Provisional Application No. 60/725,327 filed 12 Oct 2005 (HHS 
Reference No. E-166-2005/0-US-01)
Licensing Contact: Michael Shmilovich; 301/435-5019; 
[email protected]

    Available for licensing and commercial development is a 
hydropneumatic fluid control system in which cell culture media is 
perfused through a bioreactor by gas pressure where the direction of 
the gas directs the direction of perfusion. The gas can also act to 
regulate the pH of the cell culture media. Containers holding the cell 
culture media are situated on either side of an axis of rotation of a 
platform. The weight of the container as it fills with media forces the 
platform to oscillate. The oscillation actuates a piston--also coupled 
to the platform--which regulates a valve that switches the flow of gas 
to the other container. This system does not use electricity and, with 
an appropriate gas mixture, saturates cell culture media with gas.
    In addition to licensing, the technology is available for further

[[Page 1545]]

development through collaborative research opportunities with the 
inventors.

A Knockout Mouse for Transcription Factor Nurr1

Dr. Vera Nikodem (NIDDK)
HHS Reference No. E-024-1999/0--Research Tool
Licensing Contact: Marlene Shinn-Astor; 301/435-4426; 
[email protected]

    Transcriptional factor Nurr1 is an obligatory factor for 
neurotransmitter dopamine biosynthesis only in ventral midbrain as 
demonstrated by the Nurr1 genomic locus inactivation using homologous 
recombination.
    From a neurological and clinical perspective, it suggests an 
entirely new mechanism for dopamine depletion in a region where 
dopamine is known to be involved in Parkinson's disease. Clinically, 
our findings indicate that activation of Nurr1 may be therapeutically 
useful for Parkinson's disease patients; therefore, the mice would be 
useful in Parkinson's disease research.

    Dated: January 3, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-86 Filed 1-9-06; 8:45 am]
BILLING CODE 4140-01-P